1.Date of the shareholders’ meeting resolution:2021/10/27
2.Name and title of the managerial officer with permission to engage in competitive conduct:
Director        Tessie Che
Director        Michael Chang, Representative of OBI Pharma Inc.
Director        Frank Chen, Representative of OBI Pharma Inc.
Director        Ming-Tain Lai, Representative of OBI Pharma Inc.
Director        Tamon Tseng, Representative of Hui Hong Investment Co. Ltd
Supervisor    Wan-Fang Ting
3.Items of competitive conduct in which the officer is permitted to engage: Scope of business similar to that of the Company.
4.Period of permission to engage in the competitive conduct: Duration of serving as a director of the Company.
5.Circumstances of the resolution (please describe the results of voting in accordance with Article 209 of the Company Act):
The resolution was adopted by a large majority of two thirds of the shareholders of whom have voting rights and were present at the Annual Shareholders’ Meeting
6.If the permitted competitive conduct belongs to the operator of a mainland China enterprise, the name and title of the directors (if it is not the operator of a mainland China enterprise, please enter “N/A” below): Not applicable
7.Company name of the mainland China enterprise and the officer’s position in the enterprise: Not applicable
8.Address of the mainland China enterprise: Not applicable
9.Operations of the mainland China enterprise: Not applicable
10.Impact on the company’s finance and business: Not applicable
11.If the directors have invested in the mainland China enterprise, the monetary amount of the investment and their shareholding ratio: Not applicable
12.Any other matters that need to be specified: None